TriLink BioTechnologies, a unit of Maravai LifeSciences, said it plans to expand its mRNA manufacturing operations to meet growing demand from late-stage drug developers.
The new 32,000-square-foot facility, located near the company’s San Diego headquarters, will be able to produce gene edited cell therapies, protein replacement therapies, vaccines and more, the company said in a May 24 press release.
TriLink didn't disclose the cost of the project. The company said its new mRNA production site is nearing completion.
“Our team took great care in building and designing our new facility—it’s truly been a labor of love,” Rob Carpenter, TriLink’s vice president of engineering, said in the release.
Aside from increased mRNA production capacity, TriLink will offer in-house analytical services at the site.
Drug manufacturers have been on a tear expanding their mRNA production capacity in the wake of the COVID-19 pandemic. Earlier this month, Danaher subsidiary Aldevron announced plans to grow its mRNA operations to include lipid nanoparticle encapsulation and aseptic fill-finish capabilities.
Plus, last March, Moderna picked Kenya as the site for its $500 million mRNA vaccine manufacturing push on the African continent. But that was just one play in the mRNA specialist's multiyear global expansion.